Email Alert RSS
Volume 12 Issue 4
Jul.  2021
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2021  >  12(4): 445-449
CHEN Wen, ZHOU Zhou. Application of Genetic Testing in Precision Medicine for Coronary Heart Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 445-449. doi: 10.12290/xhyxzz.2021-0418
Citation: CHEN Wen, ZHOU Zhou. Application of Genetic Testing in Precision Medicine for Coronary Heart Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 445-449. doi: 10.12290/xhyxzz.2021-0418
shu

Application of Genetic Testing in Precision Medicine for Coronary Heart Disease

doi: 10.12290/xhyxzz.2021-0418

  • Center of Laboratory Medicine, State Key Laboratory of Cardiovascular Diseases, Beijing Key Laboratory for Molecular Diagnostics of Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing 100037, China

Funds:

National Natural Science Foundation of China 82070326

CAMS Innovation Fund for Medical Sciences 2016-I2M-1-016

More Information
  • Corresponding author: ZHOU Zhou  Tel: 86-10-88398055, E-mail: fwcomd@126.com
  • Received Date: 2021-05-24
  • Accepted Date: 2021-07-05
  • Publish Date: 2021-07-30
    Abstract
  • Precision medicine is a medical method that fully considers the differences of individual patients in gene, environment, life style, and so on in the process of diagnosis and treatment. Gene testing is an important way to realize precision medicine. Since the human genome data was analyzed, people have a deeper understanding of the role of genetic factors in the occurrence, development and prognosis of cardiovascular diseases. The emerging precision medicine improves the prevention and treatment of diseases through big data, promotes the progress of genetic research on cardiovascular diseases, and sets the foundation of individualized medicine, which organically combines clinical medicine, basic medicine, and transformational medicine. Genetic variation and gene polymorphism are important factors leading to coronary heart disease. We can not only identify people at high risk of coronary heart disease, but also formulate the best prevention and treatment strategies according to different molecular pathological pathways by genetic detection. All of these approaches promote the application of precision medicine. This review focused on the application of genetic testing in the prevention, diagnosis, and treatment of coronary heart disease and its related diseases.
    • FullText(HTML)
  • loading
    • References(37)
  • [1] 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2019概要[J]. 中国循环杂志, 2020, 35: 833-852. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXH202009001.htm

    The Writing Committee of the Report on Cardiovascular Health Diseases in China. Summary of China Cardiovascular Health and Disease Report 2019[J]. Zhongguo Xunhuan Zazhi, 2020, 35: 833-852. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXH202009001.htm
    [2] Truett J, Cornfield J, Kannel W. A multivariate analysis of the risk of coronary heart disease in Framingham[J]. J Chronic Dis, 1967, 20: 511-524. doi:  10.1016/0021-9681(67)90082-3
    [3] Andersson C, Johnson AD, Benjamin EJ, et al. 70-year legacy of the Framingham Heart Study[J]. Nat Rev Cardiol, 2019, 16: 687-698. doi:  10.1038/s41569-019-0202-5
    [4] Chambless LE, Folsom AR, Sharrett AR, et al. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study[J]. J Clin Epidemiol, 2003, 56: 880-890. doi:  10.1016/S0895-4356(03)00055-6
    [5] Scheltens T, Verschuren WM, Boshuizen HC, et al. Estimation of cardiovascular risk: a comparison between the Framingham and the SCORE model in people under 60 years of age[J]. Eur J Cardiovasc Prev Rehabil, 2008, 15: 562-566. doi:  10.1097/HJR.0b013e3283063a65
    [6] 中国心血管病风险评估和管理指南编写联合委员会. 中国心血管病风险评估和管理指南[J]. 中华预防医学杂志, 2019, 34: 4-28. doi:  10.3760/cma.j.issn.0253-9624.2019.01.002

    Chinese Joint Committee on the Preparation of Guidelines for Risk Assessment and Management of Cardiovascular Disea-ses. The Joint Task Force for Guideline on the Assessment and Management of Cardiovascular Risk in China[J]. Zhonghua Yufang Yixue Zazhi, 2019, 34: 4-28. doi:  10.3760/cma.j.issn.0253-9624.2019.01.002
    [7] 刘晓聪, 冯颖青, 陈纪言. 心血管疾病风险评估模型研究进展[J]. 中国实用内科杂志, 2021, 41: 428-433.

    Liu XC, Feng YQ, Chen JY. Advances in cardiovascular disease risk assessment models[J]. Zhongguo Shiyong Neike Zazhi, 2021, 41: 428-433.
    [8] Nomura A, Sato T, Tada H, et al. Polygenic risk scores for low-density lipoprotein cholesterol and familial hypercholesterolemia[J]. J Human Genetics, 2021. doi: 10.1038/s10038-021-00929-7.[Epub ahead of print].
    [9] Elliott J, Bodinier B, Bond TA, et al. Predictive Accuracy of a Polygenic Risk Score-Enhanced Prediction Model vs a Clinical Risk Score for Coronary Artery Disease[J]. JAMA, 2020, 323: 636-645. doi:  10.1001/jama.2019.22241
    [10] Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids[J]. Nature, 2010, 466: 707-713. doi:  10.1038/nature09270
    [11] Willer CJ, Schmidt EM, Sengupta S, et al. Discovery and refinement of loci associated with lipid levels[J]. Nat Genet, 2013, 45: 1274-1283. doi:  10.1038/ng.2797
    [12] Sun D, Zhou T, Heianza Y, et al. Type 2 Diabetes and Hypertension[J]. Circ Res, 2019, 124: 930-937. doi:  10.1161/CIRCRESAHA.118.314487
    [13] Saleheen D, Zhao W, Young R, et al. Loss of Cardioprotective Effects at the ADAMTS7 Locus as a Result of Gene-Smoking Interactions[J]. Circulation, 2017, 135: 2336-2353. doi:  10.1161/CIRCULATIONAHA.116.022069
    [14] Roberts R, Chang CC, Hadley T. Genetic Risk Stratification: A Paradigm Shift in Prevention of Coronary Artery Disease[J]. JACC Basic Transl Sci, 2021, 6: 287-304. doi:  10.1016/j.jacbts.2020.09.004
    [15] Koyama S, Ito K, Terao C, et al. Population-specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci for coronary artery disease[J]. Nat Genet, 2020, 52: 1169-1177. doi:  10.1038/s41588-020-0705-3
    [16] Mega JL, Stitziel NO, Smith JG, et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials[J]. Lancet, 2015, 385: 2264-2271. doi:  10.1016/S0140-6736(14)61730-X
    [17] Khera AV, Emdin CA, Drake I, et al. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease[J]. N Engl J Med, 2016, 375: 2349-2358. doi:  10.1056/NEJMoa1605086
    [18] Mega JL, Stitziel NO, Smith JG, et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials[J]. Lancet, 2015, 385: 2264-2271. doi:  10.1016/S0140-6736(14)61730-X
    [19] Nelson CP, Goel A, Butterworth AS, et al. Association analyses based on false discovery rate implicate new loci for coronary artery disease[J]. Nat Genet, 2017, 49: 1385-1391. doi:  10.1038/ng.3913
    [20] Abraham G, Havulinna AS, Bhalala OG, et al. Genomic prediction of coronary heart disease[J]. Eur Heart J, 2016, 37: 3267-3278. doi:  10.1093/eurheartj/ehw450
    [21] Wang J, Dron JS, Ban MR, et al. Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically[J]. Arterioscler Thromb Vasc Biol, 2016, 36: 2439-2445. doi:  10.1161/ATVBAHA.116.308027
    [22] Berberich AJ, Hegele RA. The complex molecular genetics of familial hypercholesterolaemia[J]. Nat Rev Cardiol, 2019, 16: 9-20. doi:  10.1038/s41569-018-0052-6
    [23] Hu P, Dharmayat KI, Stevens CAT, et al. Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis[J]. Circulation, 2020, 141: 1742-1759. doi:  10.1161/CIRCULATIONAHA.119.044795
    [24] Shi HW, Yang JG, Wang Y, et al. The Prevalence of Familial Hypercholesterolemia (FH) in Chinese Patients With Acute Myocardial Infarction (AMI): Data From Chinese Acute Myocardial Infarction (CAMI) Registry[J]. Front Cardiovasc Med, 2020, 7: 160. doi:  10.3389/fcvm.2020.00160
    [25] Trinder M, Li X, Decastro ML, et al. Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia[J]. J Am Coll Cardiol, 2019, 74: 512-522. doi:  10.1016/j.jacc.2019.05.043
    [26] Perez De Isla L, Alonso R, Watts GF, et al. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up [J]. J Am Coll Cardiol, 2016, 67: 1278-1285. http://www.researchgate.net/publication/298329532_Attainment_of_LDL-Cholesterol_Treatment_Goals_in_Patients_With_Familial_Hypercholesterolemia
    [27] Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Conse[J]. J Am Coll Cardiol, 2016, 68: 92-125. doi:  10.1016/j.jacc.2016.03.519
    [28] Sturm AC, Knowles JW, Gidding SS, et al. Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel[J]. J Am Coll Cardiol, 2018, 72: 662-680. doi:  10.1016/j.jacc.2018.05.044
    [29] Sibbing D, Aradi D, Alexopoulos D, et al. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y(12) Receptor Inhibitor Treatment in Percutaneous Coronary Intervention[J]. JACC Cardiovasc Interv, 2019, 12: 1521-1537. doi:  10.1016/j.jcin.2019.03.034
    [30] Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med, 2009, 360: 363-375. doi:  10.1056/NEJMoa0808227
    [31] Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis[J]. J Am Coll Cardiol, 2009, 103: 806-811. http://www.sciencedirect.com/science/article/pii/S0002914908020973
    [32] Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention[J]. Eur Heart J, 2009, 30: 916-922. http://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsRW5nTmV3UzIwMjEwMzAyEiA1MWIxOGRiNzhhYzgwODEwZmExYzMyMDkzMDZkYzhhNBoINXAzN294ZGY%3D
    [33] Claassens DMF, Vos GJA, Bergmeijer TO, et al. A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI[J]. N Engl J Med, 2019, 381: 1621-1631. doi:  10.1056/NEJMoa1907096
    [34] Pereira NL, Farkouh ME, So D, et al. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial[J]. JAMA, 2020, 324: 761-771. doi:  10.1001/jama.2020.12443
    [35] Ntaios G, Milionis H. Low-density lipoprotein cholesterol lowering for the prevention of cardiovascular outcomes in patients with ischemic stroke[J]. Int J Stroke, 2019, 14: 476-482. http://www.researchgate.net/publication/333135554_Low-density_lipoprotein_cholesterol_lowering_for_the_prevention_of_cardiovascular_outcomes_in_patients_with_ischemic_stroke
    [36] Hou Q, Li S, Li L, et al. Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies[J]. Medicine (Baltimore), 2015, 94: e1268. http://europepmc.org/articles/PMC4635788/
    [37] Pandya A, Zhu J, Spahillari A. Cost-effectiveness of Statin Use Guidelines-Reply[J]. JAMA Cardiol, 2021, 6: 364. http://www.researchgate.net/publication/347678797_Cost-effectiveness_of_Statin_Use_Guidelines-Reply?_sg=yYyha2Mfsl-88re-ky_x0u7iiSxbucbGiY3KCA0DmmVjOsHZGvldgH_quApgduRkyXrAB2BzpADFSAk
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (471) PDF downloads(92) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return